Cell-free DNA (cfDNA) is easily accessible in peripheral blood and can be used as
biomarkers for cancer diagnostics, prognostics, and therapeutics. The applications of cfDNA …

Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …

Purpose: Comprehensive genomic profiling (CGP) is of increasing value for patients with
metastatic castration-resistant prostate cancer (mCRPC). mCRPC tends to metastasize to …

Prostate cancer (PCa) is the most diagnosed malignancy in the men worldwide. Cancer
stem cells (CSCs) are the sub-population of cells present in the tumor which possess unique …

Purpose: Cross-resistance renders multiple lines of androgen receptor (AR) signaling
inhibitors increasingly futile in metastatic castration-resistant prostate cancer (mCRPC). We …

Background Metastatic prostate cancer is a clonally heterogeneous disease state
characterized by progressive somatic perturbations. The aim of this study was to identify cell …

Molecular heterogeneity characterizes tumours' evolution and adaptation and, because of its
dynamics and continuous changes under external pressure, it is one of the major causes of …

Introduction The extensive heterogeneity of prostate cancer (PCa) and multilayered
complexity of progression to castration-resistant prostate cancer (CRPC) have contributed to …

Abiraterone acetate (AA) has been proven effective for metastatic castration-resistant
prostate cancer (mCRPC), and it has been proposed that adaptive AA may reduce toxicity …

Background The androgen receptor (AR) remains a critical driver in metastatic castration-
resistant prostate cancer (mCRPC). Profiling AR aberrations in both circulating DNA and …